secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-10-05T21:00:37+00:00
Accession:  0001437749-26-032042
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

NRx Defense Systems awarded DARPA prime contract worth up to $11.2M for SPARC-TMS trial
--------------------------------------------------------------------------------

- NRx Defense Systems, an NRx Pharmaceuticals subsidiary, won a DARPA prime contract with aggregate value about $11.2 million and $6.7 million initially obligated.
- The contract has an 18-month performance period and milestone payments; DARPA receives a nonexclusive license while NRx Defense retains ownership of inventions.
- SPARC-TMS will evaluate single-day robotic neuronavigated TMS plus NRX-101 for treatment-resistant depression; FDA-approved trial NCT07227103 is expected to begin enrolling.
- Partners include HOPE Therapeutics, Harvard Medical School's McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.
- If replicated, results could support an FDA registration study; DARPA cited 8.9 million American adults and a $44 billion burden of treatment-resistant depression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926032042/0001437749-26-032042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926032042/nrxp20261005_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer